Vaccines

IDT Biologika looks back on more than 100 years in the manufacture of vaccines. This incredible legacy is the foundation of unparalleled expertise that goes into development and manufacture of clients’ products. Many vaccines developed by IDT Biologika with pharmaceutical manufacturing companies over the last two decades are used to protect human populations from infectious diseases such as tuberculosis, AIDS, malaria, Dengue fever, Ebola virus, and cancer. And, of course, we collaborated on overcoming the COVID-19 pandemic.

At IDT Biologika, our unparalleled experience in processes based on live viruses is used in every project to find the best ways of optimizing product development for our clients in preparation for clinical manufacturing. We have developed a strong understanding through our work with hundreds of processes and offer comprehensive support in terms of GMP, quality assurance, analytical methods, and regulatory requirements. We offer virtually every technology that has been used in the development of processes for viral vaccines, enabling us to offer unparalleled freedom of choice in finding the best options for your product.

For customers that have completed initial development work or are already in clinical stages when they come to us, we offer expertise in process development and process transfer, ensuring a seamless, risk-mitigated move of your product and process to IDT Biologika.

Our expertise in multiple technologies used in upstream and downstream processes allows us to accommodate the unique and individual nature of every contract manufacturing customer’s project. The technologies and equipment are automated and engineered so that projects can be easily scaled, contributing to robust processes from development into GMP manufacturing. Our teams are cross-trained, which further contributes to a successful scale-up process as there is a continuity of process knowledge as the project moves through clinical phases to commercial manufacturing.

IDT Biologika provides sterile liquid and lyophilized fill-finish of vaccine products in vials and pre-filled syringes at clinical and commercial scale. We are continuing to grow capacity in our state-of-the-art, high-speed filling lines housed in dedicated buildings. We offer aseptic fill-finish, lyophilization, and secondary packaging at our facility in Europe.